Literature DB >> 10682233

Central nervous system side effects associated with zolpidem treatment.

L C Toner1, B M Tsambiras, G Catalano, M C Catalano, D S Cooper.   

Abstract

Zolpidem is one of the newer medications developed for the treatment of insomnia. It is an imidazopyridine agent that is an alternative to the typical sedative-hypnotic agents. Zolpidem use is gaining favor because of its efficacy and its side effect profile, which is milder and less problematic than that of the benzodiazepines and barbiturates used to treat insomnia. Still, side effects are not uncommon with zolpidem use. We report a series of cases in which the patients developed delirium, nightmares and hallucinations during treatment with zolpidem. We will review its pharmacology, discuss previous reports of central nervous system side effects, examine the impact of drug interactions with concurrent use of antidepressants, examine gender differences in susceptibility to side effects, and explore the significance of protein binding in producing side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682233     DOI: 10.1097/00002826-200001000-00011

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  29 in total

1.  Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Authors:  W Joseph Herring; Kathleen M Connor; Ellen Snyder; Duane B Snavely; Ying Zhang; Jill Hutzelmann; Deborah Matzura-Wolfe; Ruth M Benca; Andrew D Krystal; James K Walsh; Christopher Lines; Thomas Roth; David Michelson
Journal:  J Clin Sleep Med       Date:  2016-09-15       Impact factor: 4.062

2.  A Case Report of Zolpidem-Induced Somnambulism.

Authors:  Ashish Sharma; Vijay K Dewan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  Adverse reactions to zolpidem: case reports and a review of the literature.

Authors:  Takuji Inagaki; Tsuyoshi Miyaoka; Seiichi Tsuji; Yasushi Inami; Akira Nishida; Jun Horiguchi
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  New-onset transient hallucinations possibly due to eszopiclone: a case study.

Authors:  Harpreet S Duggal
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

5.  Initiation of illusions after combination of zolpidem and paroxetine in a young woman: a case report.

Authors:  Demetris Skourides; Lampros Samartzis
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-19

6.  Association between GABA(A) receptor subunit gene cluster and zolpidem-induced complex sleep behaviors in Han Chinese.

Authors:  Jui-Hsiu Tsai; Pinchen Yang; Hung-Hsun Lin; Kuang-Hung Cheng; Yi-Hsin Yang; Ming-Tsang Wu; Cheng-Chung Chen
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

Review 7.  An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.

Authors:  Kayla Janto; J Roxanne Prichard; Snigdha Pusalavidyasagar
Journal:  J Clin Sleep Med       Date:  2018-08-15       Impact factor: 4.062

8.  Two cases of zolpidem-associated homicide.

Authors:  Cheryl M Paradis; Lawrence A Siegel; Stuart B Kleinman
Journal:  Prim Care Companion CNS Disord       Date:  2012-08-23

Review 9.  Hypnosedative-induced complex behaviours : incidence, mechanisms and management.

Authors:  Christian R Dolder; Michael H Nelson
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2009 Jan-Mar       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.